DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligibl

Trial Details

NCT ID
NCT04792489
Phase
PHASE2
Sponsor
Miltenyi Biomedicine GmbH
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • zamtocabtagene autoleucel (MB-CART2019.1)
  • Cyclophosphamide
  • Fludarabine
  • Bendamustine
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • La Jolla, California, United States|32.84727,-117.2742
  • Stanford, California, United States|37.42411,-122.16608

Key Eligibility Criteria

  • Histologically confirmed B-cell non-Hodgkin's lymphoma:
  • DLBCL cohort (both cohorts)
  • DLBCL or associated subtype, defined by WHO 2016 classification
  • DLBCL not otherwise specified (NOS)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →